Genentech wins approval for new Herceptin indication

The FDA has approved Genentech's application to extend the approval for Herceptin to be used by women who have had initial therapy for breast cancer. Data suggests that Herceptin can reduce the recurrence of breast cancer by half. The agency approved Herceptin eight years ago as a treatment for advanced breast cancer.

- here's the AP report [1] on Herceptin